Our specific objectives were to determine, 1) if MSA or γT (at two different doses, shown as γT1 and γT2) alone possesses anti-proliferative effects against prostate tumorigenesis in vivo, and 2) whether two different combinations of these agents - MSA + γT1 and/or MSA + γT2 are better than either MSA or γT alone. The gene discussed is ITGB3; the disease is male reproductive organ cancer.